1. Home
  2. MXL vs TGTX Comparison

MXL vs TGTX Comparison

Compare MXL & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MaxLinear Inc.

MXL

MaxLinear Inc.

HOLD

Current Price

$91.97

Market Cap

8.5B

Sector

Technology

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$55.12

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MXL
TGTX
Founded
2003
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.5B
8.5B
IPO Year
2009
2008

Fundamental Metrics

Financial Performance
Metric
MXL
TGTX
Price
$91.97
$55.12
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
5
Target Price
$41.67
$49.80
AVG Volume (30 Days)
3.3M
2.6M
Earning Date
04-23-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
46.08
1746.67
EPS
N/A
0.12
Revenue
$478,596,000.00
$2,785,000.00
Revenue This Year
$22.10
$49.08
Revenue Next Year
$10.70
$26.69
P/E Ratio
N/A
$463.75
Revenue Growth
N/A
N/A
52 Week Low
$12.77
$25.37
52 Week High
$128.30
$59.30

Technical Indicators

Market Signals
Indicator
MXL
TGTX
Relative Strength Index (RSI) 50.24 60.89
Support Level $74.01 $28.57
Resistance Level $105.27 $57.38
Average True Range (ATR) 11.69 2.39
MACD -1.63 -0.42
Stochastic Oscillator 27.41 51.84

Price Performance

Historical Comparison
MXL
TGTX

About MXL MaxLinear Inc.

MaxLinear Inc is a provider of radio frequency and mixed-signal integrated circuits for cable and satellite broadband communications, the connected home, and for data center, metro, and long-haul fiber networks. The company's radio frequency receiver products capture and process digital and analog broadband signals to be decoded for various applications. Its product options include both radio frequency receivers and radio frequency receiver systems-on-chips. The company's products enable the distribution and display of broadband video and data content in a wide range of electronic devices.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: